MissionIRNewsBreaks – Earth Science Tech, Inc. (ETST) Expands Presence in Blossoming Hemp-Based CBD Market

Earth Science Tech (OTC: ETST), an innovative biotech company focused on the cannabidiol (“CBD”), nutraceutical and pharmaceutical fields, is on track to increase growth and broaden its presence in the cannabis industry. An article discussing the company reads: “The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://ibn.fm/ZZbYA). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.”

To view the full article, visit http://ibn.fm/mHMjv

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. For more information, visit the company’s website at www.EarthScienceTech.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Sets Teleconference to Discuss FY2017 Results

Global life sciences company Pressure BioSciences, Inc. (OTCQB: PBIO) this morning announced that it plans to host a teleconference to discuss its fourth quarter and fiscal year 2017 financial results and to provide a business update. The teleconference is scheduled for Tuesday, April 3, 2018, at 4:30 PM EDT. Those interested in participating in the call can do so live by dialing (877) 407-8031 in North America or (201) 689-8031 from international locations. The verbal passcode for the teleconference is ‘PBI Fourth Quarter and FY2017 Financial Call & Business Update’. A replay of the call will be made available beginning Wednesday, April 4, 2018, for those unable to participate in the live teleconference. This replay will be accessible via telephone and the company’s website for 30 days. The replay will be reviewable by dialing (877) 481-4010 in North America or (919) 882-2331 from international locations, using replay ID number 27377.

To view the full press release, visit http://ibn.fm/jciYv

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. For more information, visit the company’s website at www.PressureBiosciences.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech, Inc. (ETST) Sees Explosive Sales Growth in 2018

• Nickolas Tabraue, ETST president, gives up COO position to Gagan Hunter, noting that the move completes the ‘puzzle’ to drive company to new heights in alternative medicine market


• Biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing high-grade, industrial hemp cannabidiol (CBD)


• Company projects a breakout year in 2018, in part due to revamping of its executive team and introducing a new marketing strategy for its repositioned and repackaged line of industrial hemp products

Earth Science Tech, Inc. (OTC: ETST), by naming Gagan Hunter as its new COO, has completed a transition, positioning the company to reach ‘new heights’ with a new team in place and a revamped marketing strategy for its industrial hemp-sourced line as a cannabinoid complex, as detailed by Nickolas Tabraue, company director and president, in a recent news release (http://ibn.fm/kCt0l). Tabraue, who served as COO prior to the appointment of Hunter, said that ETST has positioned itself for ‘explosive sales growth’ in 2018 (http://ibn.fm/wBXbl).

Hunter said that he looks forward to strengthening the company’s operations. He has 20 years of experience in the natural products industry, joining a number of seasoned additions to the ETST team. Earlier, the company put in place the team of Jill Buzan as chief sales officer, Sergio Castillo as chief marketing officer, and Gabriel Aviles as chief learning officer (http://ibn.fm/pvDSn).

Tabraue added, “I feel that we finally have the last piece of our puzzle in place to take ETST to new heights. Gagan has many great ideas to implement that will help the company work more efficiently and with greater organization. We now have every major role managed by passionate, likeminded individuals to truly make ETST an innovative, trusted brand in the alternative medicine space.”

Earth Science Tech is an innovative biotech company based in Doral, Florida. It markets a repositioned and repackaged line of High Grade Full Spectrum cannabidiol (CBD) oil products. Focused on manufacturing and marketing cannabinoid products to the pharmaceutical and nutraceutical markets, it also conducts R&D for low-cost, non-invasive medical devices.

The company holds three wholly owned subsidiaries, including:

• Earth Science Pharmaceutical, which develops medical diagnostic tools and vaccines;


• Cannabis Therapeutics, an emerging biotechnology company; and


• KannaBidioiD, which is focused on cannabidiol production and distribution in the recreational space.

For more information, visit the company’s website at www.EarthScienceTech.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

BioSig Technologies, Inc. (BSGM) to Participate in Bates College’s Purposeful Work Internship Program in 2018

• Kenneth L. Londoner, chairman and CEO of BSGM, said in a news release that interns will be offered a ‘360-degree overview’ of the business within an entrepreneurial environment


• Firm is a development stage medical device company with products that assist electrophysiologists; it is also assembling a portfolio of software tools for arrhythmia treatments


• BioSig values global electrophysiology (EP) market at $4.6 billion, with research firm projecting that market will reach $4.73 billion by 2019


• BioSig recently named first two members to new advisory board

BioSig Technologies, Inc. (OTCQB: BSGM) will be offering summer internships to Bates College students in 2018 as part of that school’s Purposeful Work initiative. Bates, based in Lewiston, Maine, has an internship component as part of that program. The Bates interns at BioSig will be compensated, the company announced (http://ibn.fm/EGmQK). Core employers in the 2017 Bates Purposeful Work program included Oppenheimer Co. in Boston; Memorial Sloan Kettering Cancer Center in New York; L.L. Bean, Inc. in Maine; and the American Chamber of Commerce in China.

In a news release, Kenneth L. Londoner, chairman and CEO of BSGM, said, “We were impressed with the consistent commitment to excellence that Bates demonstrates, and we are confident that our partnership will allow us to take both of our programs to the next level.” He added that the interns would be given a ‘360-degree overview’ of the business.

BioSig is a Santa Monica, California-based, development stage medical device company with an office in Austin, Texas. The company is developing a proprietary biomedical signal-processing platform and is preparing to commercialize its Precise Uninterrupted Real-time evaluation of Electrograms, or PURE EP™ System. In its spring 2018 corporate presentation, BioSig valued the electrophysiology marketplace at $4.6 billion (http://ibn.fm/912BY), while research firm Markets and Markets projects that the marketplace will reach $4.73 billion by 2019, growing at a CAGR of 10.3 percent from 2014-2019 (http://ibn.fm/ViYSt).

PURE EP is a unique cardiac signal acquisition and display system engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig is also assembling a portfolio of software tools designed for electrophysiologists and arrhythmia treatments.

BioSig also recently announced the formation of an advisory board to help in such areas as partnerships, government affairs, intellectual property and capital markets, and it named the first two members, Kent Bennett Williams, CEO and principal of Vista Asset Management, LLC, and Dr. Ramachandra Malya, M.D., a medical director and nephrologist (http://ibn.fm/ZNmax). In announcing the additions, Londoner stated, “We wanted to appoint a proactive Advisory Board, which brings fresh thinking, skills and expertise to enhance our company’s performance. Kent and Dr. Malya bring impressive career achievements, which will deliver immediate impact in the top priority areas of our business.”

For more information, visit the company’s website at www.BioSigTech.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Strong Management Team Leading Net Element, Inc. (NASDAQ: NETE) toward Organic Growth, Blockchain-Focused Developments in 2018

• Leadership team leveraging years of experience to sustainably meet company’s goals


• Organic growth, single payment processing platform that integrates any payment ecosystem among top goals for 2018 and beyond


• Payment processing industry set to reach $2.2 trillion by 2021

On the heels of a remarkable performance in 2017, which ended with the strongest balance sheet in the company’s history and a $7.55 million investment, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is targeting sustained organic growth across all sectors, as well as significant advancements in blockchain developments. With a highly experienced and committed management team at the helm, bringing a unique blend of vision, leadership and creative energy, the company looks all but set to achieve its goals for 2018 and beyond.

The overall vision, strategy and execution of Net Element’s mission are in the hands of its CEO and director, Oleg Firer. Recognized as one of the top entrepreneurs in Florida and one of the most influential people in Miami by publications such as Business Leader Magazine, Forbes and Poder Magazine, Firer served as executive chairman of Unified Payments before taking his current position. During his tenure, Unified Payments was ranked as the fastest-growing company in 2012 by Inc. Magazine, having grown its revenues by 23,646 percent over a three-year period. Unified Payments, which provides various payment processing services, including mobile payment acceptance to small- and medium-sized merchants, was acquired by Net Element in April 2013. Firer is leveraging his experience and skills to help drive Net Element’s sustained growth and achieve the group’s long-term goal of creating a single, international processing platform.

The company’s chief technology officer, Andrey Krotov, is an experienced software engineer originating from Russia. He first joined Net Element as a senior software developer in early 2011 but soon became head of Net Element Russia’s development department, where he remained until March 2014, when he took his current management position. He previously worked as a software engineer and senior software engineer with software development companies such as Interactive Tribe GmbH and Artsofte. With a master’s degree from Russia’s Ural State Technical University, Krotov has focused throughout his career on the creation of proprietary intellectual property and the management of both local and outsourced software developing teams. He will use his expertise to continue overseeing and coordinating Net Element’s product development efforts.

With a BS in accounting from Florida State University and vast experience in providing financial and accounting services to a number of companies, Jonathan New has served as chief financial officer of Net Element since 2008. Before joining Net Element, he provided auditing, reporting and corporate accounting services to different public companies. He is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants.

Net Element’s chief legal officer and secretary, Steven Wolberg, is an experienced attorney who has been practicing for years in both the United States and South Africa. Wolberg is a member of the Massachusetts Bar Association; he received his bachelor of laws from the University of Witwatersrand in Johannesburg and his juris doctorate from the New England School of Law in Boston. He has served as chief legal officer of Net Element since 2013, before which he served in various capacities with Acies Corporation, a financial services and payment processing company, and several other firms.

As the global payments industry continues to thrive and is expected to surpass $2.2 trillion dollars in volume by 2021 (http://ibn.fm/vBQfP), Net Element is set to strengthen its position as a leading developer and provider of innovative payment solutions. Supporting electronic payments acceptance in a multi-channel environment, from mobile devices to blockchain, e-commerce and point-of-sale, the company remains focused on continuing its organic growth, developing innovative payment solutions, especially in the field of blockchain and, ultimately, creating a single onboarding and transaction processing platform that will accommodate both local and international payment ecosystems.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Named to the CSE25 Index

• Pivot Pharmaceuticals attains prestigious CSE25 status


• Recent acquisitions have extended the company’s portfolio in the cannabis space


• Numerous pharmaceutical and nutraceutical products in development pipeline

Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://ibn.fm/4S2cb). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.

“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”

In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.

The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.

Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.

Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://ibn.fm/0iuTk). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.

For more information, visit the company’s website at www.PivotPharma.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html